Answered

Discover the best answers at Westonci.ca, where experts share their insights and knowledge with you. Get accurate and detailed answers to your questions from a dedicated community of experts on our Q&A platform. Join our platform to connect with experts ready to provide precise answers to your questions in different areas.

About 40% of metastatic melanoma patients treated with anti-PD-1 or anti-PD-L1 therapy develop some antitumor immune responses that delay cancer progression or even lead to complete remissions. Why do you think that some patients respond to checkpoint blockade therapy, while others do not?

Sagot :

We appreciate your visit. Hopefully, the answers you found were beneficial. Don't hesitate to come back for more information. Thank you for your visit. We're committed to providing you with the best information available. Return anytime for more. We're glad you chose Westonci.ca. Revisit us for updated answers from our knowledgeable team.